<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29848582</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>15</Issue><PubDate><Year>2018</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e00682-18</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00682-18</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is a causative agent of hand, foot, and mouth disease and sometimes causes severe or fatal neurological complications. The amino acid at VP1-145 determines the virological characteristics of EV71. Viruses with glutamic acid (E) at VP1-145 (VP1-145E) are virulent in neonatal mice and transgenic mice expressing human scavenger receptor B2, whereas those with glutamine (Q) or glycine (G) are not. However, the contribution of this variation to pathogenesis in humans is not fully understood. We compared the virulence of VP1-145E and VP1-145G viruses of Isehara and C7/Osaka backgrounds in cynomolgus monkeys. VP1-145E, but not VP1-145G, viruses induced neurological symptoms. VP1-145E viruses were frequently detected in the tissues of infected monkeys. VP1-145G viruses were detected less frequently and disappeared quickly. Instead, mutants that had a G-to-E mutation at VP1-145 emerged, suggesting that VP1-145E viruses have a replication advantage in the monkeys. This is consistent with our hypothesis proposed in the accompanying paper (K. Kobayashi, Y. Sudaka, A. Takashino, A. Imura, K. Fujii, and S. Koike, J Virol 92:e00681-18, 2018, https://doi.org/10.1128/JVI.00681-18) that the VP1-145G virus is attenuated due to its adsorption by heparan sulfate. Monkeys infected with both viruses produced neutralizing antibodies before the onset of the disease. Interestingly, VP1-145E viruses were more resistant to neutralizing antibodies than VP1-145G viruses <i>in vitro</i> A small amount of neutralizing antibody raised in the early phase of infection may not be sufficient to block the dissemination of VP1-145E viruses. The different resistance of the VP1-145 variants to neutralizing antibodies may be one of the reasons for the difference in virulence.<b>IMPORTANCE</b> The contribution of VP1-145 variants in humans is not fully understood. In some studies, VP1-145G/Q viruses were isolated more frequently from severely affected patients than from mildly affected patients, suggesting that VP1-145G/Q viruses are more virulent. In the accompanying paper (K. Kobayashi, Y. Sudaka, A. Takashino, A. Imura, K. Fujii, and S. Koike, J Virol 92:e00681-18, 2018, https://doi.org/10.1128/JVI.00681-18), we showed that VP1-145E viruses are more virulent than VP1-145G viruses in human SCARB2 transgenic mice. Heparan sulfate acts as a decoy to specifically trap the VP1-145G viruses and leads to abortive infection. Here, we demonstrated that VP1-145G was attenuated in cynomolgus monkeys, suggesting that this hypothesis is also true in a nonhuman primate model. VP1-145E viruses, but not VP1-145G viruses, were highly resistant to neutralizing antibodies. We propose the difference in resistance against neutralizing antibodies as another mechanism of EV71 virulence. In summary, VP1-145 contributes to virulence determination by controlling attachment receptor usage and antibody sensitivity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 American Society for Microbiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudaka</LastName><ForeName>Yui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takashino</LastName><ForeName>Ayako</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Kyousuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Chikako</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Tadaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata-Yoshikawa</LastName><ForeName>Naoko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotani</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Pathogen Genomics Center, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ami</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Experimental Animal Research, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagata</LastName><ForeName>Noriyo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuta</LastName><ForeName>Katsumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Yamagata Prefectural Institute of Public Health, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuzaki</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Yamagata University Faculty of Medicine, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koike</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurovirology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan koike-st@igakuken.or.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9050-30-0</RegistryNumber><NameOfSubstance UI="D006497">Heparitin Sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="Y">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000662" MajorTopicYN="Y">veterinary</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006497" MajorTopicYN="N">Heparitin Sulfate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">animal models</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">pathogenesis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29848582</ArticleId><ArticleId IdType="pmc">PMC6052295</ArticleId><ArticleId IdType="doi">10.1128/JVI.00682-18</ArticleId><ArticleId IdType="pii">JVI.00682-18</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pallansch M, Oberste MS, Whitton JL. 2013. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p 490&#x2013;530. In Knipe D, Howley PM (ed), Fields virology, 6th ed Lippincott Williams &amp; Wilkins, Philadelphia, PA.</Citation></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. 2010. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10:778&#x2013;790. doi:10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19:424&#x2013;429. doi:10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. 2012. Crystal structure of human enterovirus 71. Science 336:1274. doi:10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, Nishimura H, Sanjoh K, Katsushima N, Itagaki T, Nagai Y, Fujii K, Koike S. 2012. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J Virol 86:5686&#x2013;5696. doi:10.1128/JVI.00020-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00020-12</ArticleId><ArticleId IdType="pmc">PMC3347270</ArticleId><ArticleId IdType="pubmed">22438546</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Ohka S, Fujii K, Koike S. 2013. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol 87:3335&#x2013;3347. doi:10.1128/JVI.02070-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02070-12</ArticleId><ArticleId IdType="pmc">PMC3592140</ArticleId><ArticleId IdType="pubmed">23302872</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y, Wu X, Yao X, Mao Q, Li X, Dong W, Wan X, Huang N, Shen X, Liang Z, Li W. 2012. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem 287:6406&#x2013;6420. doi:10.1074/jbc.M111.301622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.301622</ArticleId><ArticleId IdType="pmc">PMC3307280</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15:794&#x2013;797. doi:10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Poh CL, Sam IC, Chan YF. 2013. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol 87:611&#x2013;620. doi:10.1128/JVI.02226-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SL, Chou YT, Wu CN, Ho MS. 2011. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol 85:11809&#x2013;11820. doi:10.1128/JVI.00297-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00297-11</ArticleId><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Su PY, Liu YT, Chang HY, Huang SW, Wang YF, Yu CK, Wang JR, Chang CF. 2012. Cell surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and neuroblastoma cells. BMC Microbiol 12:162. doi:10.1186/1471-2180-12-162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-12-162</ArticleId><ArticleId IdType="pmc">PMC3478995</ArticleId><ArticleId IdType="pubmed">22853823</ArticleId></ArticleIdList></Reference><Reference><Citation>Su PY, Wang YF, Huang SW, Lo YC, Wang YH, Wu SR, Shieh DB, Chen SH, Wang JR, Lai MD, Chang CF. 2015. Cell surface nucleolin facilitates enterovirus 71 binding and infection. J Virol 89:4527&#x2013;4538. doi:10.1128/JVI.03498-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03498-14</ArticleId><ArticleId IdType="pmc">PMC4442404</ArticleId><ArticleId IdType="pubmed">25673703</ArticleId></ArticleIdList></Reference><Reference><Citation>Du N, Cong H, Tian H, Zhang H, Zhang W, Song L, Tien P. 2014. Cell surface vimentin is an attachment receptor for enterovirus 71. J Virol 88:5816&#x2013;5833. doi:10.1128/JVI.03826-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03826-13</ArticleId><ArticleId IdType="pmc">PMC4019121</ArticleId><ArticleId IdType="pubmed">24623428</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Fujii K, Koike S. 2014. Receptors for enterovirus 71. Emerg Microbes Infect 3:e53. doi:10.1038/emi.2014.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2014.49</ArticleId><ArticleId IdType="pmc">PMC4126179</ArticleId><ArticleId IdType="pubmed">26038749</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarrazin S, Lamanna WC, Esko JD. 2011. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 3:a004952. doi:10.1101/cshperspect.a004952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a004952</ArticleId><ArticleId IdType="pmc">PMC3119907</ArticleId><ArticleId IdType="pubmed">21690215</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Lee H, Hafenstein S, Kataoka C, Wakita T, Bergelson JM, Shimizu H. 2013. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog 9:e1003511. doi:10.1371/journal.ppat.1003511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003511</ArticleId><ArticleId IdType="pmc">PMC3723564</ArticleId><ArticleId IdType="pubmed">23935488</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Sam IC, Lee VS, Wong HV, Chan YF. 2017. VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology 501:79&#x2013;87. doi:10.1016/j.virol.2016.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.11.009</ArticleId><ArticleId IdType="pubmed">27875780</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua BH, Phuektes P, Sanders SA, Nicholls PK, McMinn PC. 2008. The molecular basis of mouse adaptation by human enterovirus 71. J Gen Virol 89:1622&#x2013;1632. doi:10.1099/vir.0.83676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.83676-0</ArticleId><ArticleId IdType="pubmed">18559932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Duo J, Liu J, Ma C, Zhang L, Wei Q, Qin C. 2011. A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect 13:862&#x2013;870. doi:10.1016/j.micinf.2011.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2011.04.004</ArticleId><ArticleId IdType="pubmed">21612764</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Ami Y, Wakita T, Shimizu H. 2008. Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J Virol 82:1787&#x2013;1797. doi:10.1128/JVI.01798-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01798-07</ArticleId><ArticleId IdType="pmc">PMC2258712</ArticleId><ArticleId IdType="pubmed">18057246</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Wang YF, Yu CK, Su IJ, Wang JR. 2012. Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement. Virology 422:132&#x2013;143. doi:10.1016/j.virol.2011.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.10.015</ArticleId><ArticleId IdType="pubmed">22078110</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaini Z, McMinn P. 2012. A single mutation in capsid protein VP1 (Q145E) of a genogroup C4 strain of human enterovirus 71 generates a mouse-virulent phenotype. J Gen Virol 93:1935&#x2013;1940. doi:10.1099/vir.0.043893-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.043893-0</ArticleId><ArticleId IdType="pubmed">22647370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka C, Suzuki T, Kotani O, Iwata-Yoshikawa N, Nagata N, Ami Y, Wakita T, Nishimura Y, Shimizu H. 2015. The role of VP1 amino acid residue 145 of enterovirus 71 in viral fitness and pathogenesis in a cynomolgus monkey model. PLoS Pathog 11:e1005033. doi:10.1371/journal.ppat.1005033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005033</ArticleId><ArticleId IdType="pmc">PMC4504482</ArticleId><ArticleId IdType="pubmed">26181772</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Zou Q, Chen L, Zhang H, Wang Y. 2011. Molecular analysis of virulent determinants of enterovirus 71. PLoS One 6:e26237. doi:10.1371/journal.pone.0026237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026237</ArticleId><ArticleId IdType="pmc">PMC3198388</ArticleId><ArticleId IdType="pubmed">22039449</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SC, Li WC, Chen GW, Tsao KC, Huang CG, Huang YC, Chiu CH, Kuo CY, Tsai KN, Shih SR, Lin TY. 2012. Genetic characterization of enterovirus 71 isolated from patients with severe disease by comparative analysis of complete genomes. J Med Virol 84:931&#x2013;939. doi:10.1002/jmv.23287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23287</ArticleId><ArticleId IdType="pubmed">22499017</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Fu C, Wu S, Chen X, Shi Y, Zhou B, Zhang L, Zhang F, Wang Z, Zhang Y, Fan C, Han S, Yin J, Peng B, Liu W, He X. 2014. A novel finding for enterovirus virulence from the capsid protein VP1 of EV71 circulating in mainland China. Virus Genes 48:260&#x2013;272. doi:10.1007/s11262-014-1035-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-014-1035-2</ArticleId><ArticleId IdType="pubmed">24442718</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Wu X, Huang K, Li L, Zheng L, Wan C, He ML, Zhao W. 2014. The variations of VP1 protein might be associated with nervous system symptoms caused by enterovirus 71 infection. BMC Infect Dis 14:243. doi:10.1186/1471-2334-14-243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-243</ArticleId><ArticleId IdType="pmc">PMC4101859</ArticleId><ArticleId IdType="pubmed">24886383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Sudaka Y, Takashino A, Imura A, Fujii K, Koike S. 2018. Amino acid variation at VP1-145 of enterovirus 71 determines attachment receptor usage and neurovirulence in human scavenger receptor B2 transgenic mice. J Virol 92:e00681-. doi:10.1128/JVI.00681-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00681-18</ArticleId><ArticleId IdType="pmc">PMC6052303</ArticleId><ArticleId IdType="pubmed">29848584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara A, Yoneyama T, Hashimoto I. 1983. Isolation of a temperature-sensitive strain of enterovirus 71 with reduced neurovirulence for monkeys. J Gen Virol 64:499&#x2013;502. doi:10.1099/0022-1317-64-2-499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-64-2-499</ArticleId><ArticleId IdType="pubmed">6300298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto I, Hagiwara A. 1982. Pathogenicity of a poliomyelitis-like disease in monkeys infected orally with enterovirus 71: a model for human infection. Neuropathol Appl Neurobiol 8:149&#x2013;156. doi:10.1111/j.1365-2990.1982.tb00269.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1982.tb00269.x</ArticleId><ArticleId IdType="pubmed">7048123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto I, Hagiwara A. 1982. Studies on the pathogenesis of and propagation of enterovirus 71 in poliomyelitis-like disease in monkeys. Acta Neuropathol 58:125&#x2013;132. doi:10.1007/BF00691653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00691653</ArticleId><ArticleId IdType="pubmed">6758469</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto I, Hagiwara A, Kodama H. 1978. Neurovirulence in cynomolgus monkeys of enterovirus 71 isolated from a patient with hand, foot and mouth disease. Arch Virol 56:257&#x2013;261. doi:10.1007/BF01317855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01317855</ArticleId><ArticleId IdType="pubmed">205198</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata N, Shimizu H, Ami Y, Tano Y, Harashima A, Suzaki Y, Sato Y, Miyamura T, Sata T, Iwasaki T. 2002. Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol 67:207&#x2013;216. doi:10.1002/jmv.2209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.2209</ArticleId><ArticleId IdType="pubmed">11992581</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata N, Iwasaki T, Ami Y, Tano Y, Harashima A, Suzaki Y, Sato Y, Hasegawa H, Sata T, Miyamura T, Shimizu H. 2004. Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol 85:2981&#x2013;2989. doi:10.1099/vir.0.79883-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79883-0</ArticleId><ArticleId IdType="pubmed">15448361</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellier C, Foray S, Hermine O. 2000. Regional enteritis associated with enterovirus in a patient with X-linked agammaglobulinemia. N Engl J Med 342:1611&#x2013;1612. doi:10.1056/NEJM200005253422113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200005253422113</ArticleId><ArticleId IdType="pubmed">10841685</ArticleId></ArticleIdList></Reference><Reference><Citation>Mease PJ, Ochs HD, Wedgwood RJ. 1981. Successful treatment of echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia. N Engl J Med 304:1278&#x2013;1281. doi:10.1056/NEJM198105213042107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198105213042107</ArticleId><ArticleId IdType="pubmed">6783908</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N, Bodian D. 1962. Experimental poliomyelitis following intramuscular virus injection. III. The effect of passive antibody on paralysis and viremia. Bull Johns Hopkins Hosp 111:198&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">13937699</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. 2011. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). WHO, Geneva, Switzerland.</Citation></Reference><Reference><Citation>Gwaltney JM Jr, Calhoun AM. 1970. Viral aggregation resulting in the failure to correctly identify an unknown rhinovirus. Appl Microbiol 20:390&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC376945</ArticleId><ArticleId IdType="pubmed">4320921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ida-Hosonuma M, Iwasaki T, Yoshikawa T, Nagata N, Sato Y, Sata T, Yoneyama M, Fujita T, Taya C, Yonekawa H, Koike S. 2005. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol 79:4460&#x2013;4469. doi:10.1128/JVI.79.7.4460-4469.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.7.4460-4469.2005</ArticleId><ArticleId IdType="pmc">PMC1061561</ArticleId><ArticleId IdType="pubmed">15767446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard KA, Klimstra WB, Johnston RE. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93&#x2013;103. doi:10.1006/viro.2000.0546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2000.0546</ArticleId><ArticleId IdType="pubmed">11021998</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, Wright PJ, Davidson A, Lobigs M. 2006. Virulence attenuation of dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J Gen Virol 87:2791&#x2013;2801. doi:10.1099/vir.0.82164-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.82164-0</ArticleId><ArticleId IdType="pubmed">16963737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, Hall RA, Lobigs M. 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J Virol 78:8271&#x2013;8280. doi:10.1128/JVI.78.15.8271-8280.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.8271-8280.2004</ArticleId><ArticleId IdType="pmc">PMC446099</ArticleId><ArticleId IdType="pubmed">15254199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E, Lobigs M. 2002. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J Virol 76:4901&#x2013;4911. doi:10.1128/JVI.76.10.4901-4911.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.10.4901-4911.2002</ArticleId><ArticleId IdType="pmc">PMC136177</ArticleId><ArticleId IdType="pubmed">11967307</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Pfeiffer JK. 2016. Emergence of a large-plaque variant in mice infected with coxsackievirus B3. mBio 7:e00119. doi:10.1128/mBio.00119-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00119-16</ArticleId><ArticleId IdType="pmc">PMC4817249</ArticleId><ArticleId IdType="pubmed">27025249</ArticleId></ArticleIdList></Reference><Reference><Citation>Anez G, Men R, Eckels KH, Lai CJ. 2009. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. J Virol 83:10384&#x2013;10394. doi:10.1128/JVI.01083-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01083-09</ArticleId><ArticleId IdType="pmc">PMC2753127</ArticleId><ArticleId IdType="pubmed">19656873</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickells J, Cannella M, Droll DA, Liang Y, Wold WS, Chambers TJ. 2008. Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model. J Virol 82:12510&#x2013;12519. doi:10.1128/JVI.00458-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00458-08</ArticleId><ArticleId IdType="pmc">PMC2593324</ArticleId><ArticleId IdType="pubmed">18842715</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandl CW, Kroschewski H, Allison SL, Kofler R, Holzmann H, Meixner T, Heinz FX. 2001. Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J Virol 75:5627&#x2013;5637. doi:10.1128/JVI.75.12.5627-5637.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.12.5627-5637.2001</ArticleId><ArticleId IdType="pmc">PMC114275</ArticleId><ArticleId IdType="pubmed">11356970</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva LA, Khomandiak S, Ashbrook AW, Weller R, Heise MT, Morrison TE, Dermody TS. 2014. A single-amino-acid polymorphism in chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization. J Virol 88:2385&#x2013;2397. doi:10.1128/JVI.03116-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03116-13</ArticleId><ArticleId IdType="pmc">PMC3958064</ArticleId><ArticleId IdType="pubmed">24371059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashbrook AW, Burrack KS, Silva LA, Montgomery SA, Heise MT, Morrison TE, Dermody TS. 2014. Residue 82 of the chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice. J Virol 88:12180&#x2013;12192. doi:10.1128/JVI.01672-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01672-14</ArticleId><ArticleId IdType="pmc">PMC4248890</ArticleId><ArticleId IdType="pubmed">25142598</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner CL, Hritz J, Sun C, Vanlandingham DL, Song TY, Ghedin E, Higgs S, Klimstra WB, Ryman KD. 2014. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl Trop Dis 8:e2719. doi:10.1371/journal.pntd.0002719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002719</ArticleId><ArticleId IdType="pmc">PMC3930508</ArticleId><ArticleId IdType="pubmed">24587470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman KD, Klimstra WB, Johnston RE. 2004. Attenuation of Sindbis virus variants incorporating uncleaved PE2 glycoprotein is correlated with attachment to cell-surface heparan sulfate. Virology 322:1&#x2013;12. doi:10.1016/j.virol.2004.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2004.01.003</ArticleId><ArticleId IdType="pubmed">15063111</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimstra WB, Ryman KD, Johnston RE. 1998. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J Virol 72:7357&#x2013;7366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109960</ArticleId><ArticleId IdType="pubmed">9696832</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P. 2011. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 29:4362&#x2013;4372. doi:10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd KA, DeMaso CR, Pierson TC. 2015. Genotypic differences in dengue virus neutralization are explained by a single amino acid mutation that modulates virus breathing. mBio 6:e01559-. doi:10.1128/mBio.01559-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01559-15</ArticleId><ArticleId IdType="pmc">PMC4631804</ArticleId><ArticleId IdType="pubmed">26530385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolawole AO, Smith HQ, Svoboda SA, Lewis MS, Sherman MB, Lynch GC, Pettitt BM, Smith TJ, Wobus CE. 2017. Norovirus escape from broadly neutralizing antibodies is limited to allostery-like mechanisms. mSphere 2:e00334-. doi:10.1128/mSphere.00334-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00334-17</ArticleId><ArticleId IdType="pmc">PMC5646240</ArticleId><ArticleId IdType="pubmed">29062895</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindesmith LC, Mallory ML, Debbink K, Donaldson EF, Brewer-Jensen PD, Swann EW, Sheahan TP, Graham RL, Beltramello M, Corti D, Lanzavecchia A, Baric RS. 2018. Conformational occlusion of blockade antibody epitopes, a novel mechanism of GII.4 human norovirus immune evasion. mSphere 3:e00518-17. doi:10.1128/mSphere.00518-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00518-17</ArticleId><ArticleId IdType="pmc">PMC5806210</ArticleId><ArticleId IdType="pubmed">29435493</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H. 2007. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81:9386&#x2013;9395. doi:10.1128/JVI.02856-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02856-06</ArticleId><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15:798&#x2013;801. doi:10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Aoki Y, Suto A, Ootani K, Katsushima N, Itagaki T, Ohmi A, Okamoto M, Nishimura H, Matsuzaki Y, Hongo S, Sugawara K, Shimizu H, Ahiko T. 2009. Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007. Vaccine 27:3153&#x2013;3158. doi:10.1016/j.vaccine.2009.03.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.03.060</ArticleId><ArticleId IdType="pubmed">19446185</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>